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ABSTRACT 
The low-grade inflammatory state present in obesity contributes to obesity-related 
metabolic dysregulation, including non-alcoholic steatohepatitis (NASH) and insulin 
resistance. Intercellular interactions between immune cells or between immune cells 
and hepatic parenchymal cells contribute to the exacerbation of liver inflammation 
and steatosis in obesity. The co-stimulatory molecules B7.1 and B7.2 are important 
regulators of cell-cell interactions in several immune processes; however, the role of 
B7 co-stimulation in obesity-related liver inflammation is unknown. Here, diet-
induced obesity (DIO) studies in mice with genetic inactivation of both B7.1 and B7.2 
(Dko) revealed aggravated obesity-related metabolic dysregulation, reduced insulin 
signalling in the liver and adipose tissue (AT), glucose intolerance and enhanced 
progression to steatohepatitis due to B7.1/B7.2-double deficiency. The metabolic 
phenotype of B7.1/B7.2-double deficiency upon DIO was accompanied by increased 
hepatic and AT inflammation, associated with largely reduced numbers of regulatory 
T cells (Tregs) in these organs. In order to assess the role of B7 co-stimulation in DIO 
in a non-Treg lacking environment, we performed antibody-mediated inhibition of B7 
molecules in wild-type mice in DIO. Antibody-blockade of both B7.1 and B7.2 
improved the metabolic phenotype of DIO-mice, which was linked to amelioration of 
hepatic steatosis and reduced inflammation in liver and AT. Conclusion: Our study 
demonstrates a dual role of B7 co-stimulation in the course of obesity-related sequelae, 
particularly NASH. The genetic inactivation of B7.1/B7.2 deteriorates obesity-related 
liver steatosis and metabolic dysregulation likely due to the intrinsic absence of Tregs 
in these mice rendering Dko mice a novel murine model of NASH. In contrast, 
inhibition of B7 co-stimulation under conditions where Tregs are present may provide 
a novel therapeutic approach for obesity-related metabolic dysregulation and 
especially NASH. 
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INTRODUCTION 
Obesity is associated with low-grade inflammation, liable for the development of 
insulin resistance, type 2 diabetes and non-alcoholic steatohepatitis (NASH). Immune 
cells of both the innate and adaptive immunity are implicated in this process and 
contribute to the development of hepatosteatosis and -steatitis as well as adipose 
tissue (AT) inflammation(1,2) that accompany obesity.  
 
Inflammation in the liver is the determinant factor for the progression from non-
alcoholic fatty liver disease (NAFLD), characterized by increased hepatic lipid 
accumulation, to NASH, featured by exacerbated intrahepatic inflammation, more 
intense steatosis and hepatocellular injury. Increased accumulation and activation of 
macrophages in the liver and activation of local Kupffer cells under obese conditions, 
as well as the concomitant reduction of the anti-inflammatory regulatory T cells 
(Tregs) are important parameters in diet-induced liver steatosis and tissue 
damage(3,4). Additionally, the development of AT inflammation in the course of 
obesity, further contributes to hepatosteatosis and deterioration of liver inflammation 
under obese conditions. More specifically, the accumulation of macrophages in AT 
and their interplay with infiltrated lymphocytes, such as cytotoxic CD8+ T cells, as 
well as the significant decrease of AT Tregs are phenomena mediating AT 
inflammation(1,2,5). Consecutively, cytokines/adipokines from the AT such as leptin, 
IL-1b or IL-18 create a crosstalk with the liver and can serve as sources of 
extrahepatic inflammation, thereby exacerbating hepatic steatosis(6,7). Nevertheless, 
the information about the exact cellular and molecular mechanisms governing 
obesity-related inflammation in the hepatic environment and thereby the progression 
of NAFLD to NASH is scarce. 
 
CD80 and CD86 (also designated B7.1 and B7.2) are probably the best characterised 
co-stimulatory molecules that are mainly expressed by antigen presenting cells and 
interact with CD28 and CTLA-4 on T cells, mediating positive and negative signals, 
respectively, during T cell activation(8). The importance of B7.1 and B7.2 signalling 
is defined by the fact that they participate in several immunological processes such as 
T cell proliferation, negative selection of autoreactive T cells(9), immunoglobulin 
class switching(10) and Treg development(11) and are therefore implicated in several 
pathologies such as cancer and atherogenesis(12). The role of co-stimulation in 
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regulating obesity-associated inflammation has emerged from previous studies with 
regards to the CD40-CD40L dyad(13,14), whereas less information on the role of 
B7.1 and B7.2-dependent co-stimulation exists.  
 
In this study we provide evidence that B7.1 and B7.2 have a multifaceted role in 
regulating obesity-related inflammatory reactions in the AT and especially in the liver 
and thereby the progression from NAFLD to NASH. Performing diet-induced obesity 
(DIO) in B7.1/B7.2-double deficient mice (Double-knockout; Dko), we observed 
enhanced metabolic dysregulation with glucose intolerance, insulin resistance and 
deterioration of hepatosteatosis associated with increased progression to 
hepatosteatitis, which could be ascribed to the dramatic reduction in Treg cells in 
B7.1/B7.2 double deficiency. Contrastingly, blocking both B7.1 and B7.2 with 
antibodies, but not each one alone, in wild-type mice (i.e. in the presence of normal 
Treg numbers) attenuated obesity-related metabolic dysregulation, improving glucose 
tolerance, AT inflammation and diet-induced hepatic steatosis. Together, our findings 
suggest a dual role of B7 co-stimulation in obesity-related steatohepatitis and 
metabolic dysregulation governed by the presence or absence of Tregs, and underline 
that B7.1-B7.2 co-stimulation may represent an interesting therapeutic target to limit 
obesity-related metabolic dysregulation and development of NASH. 
 
MATERIALS AND METHODS 
Detailed description of Materials and Methods is found in the Supporting Information. 
 
RESULTS 
B7.1 and B7.2 expression in obesity 
To determine the presence and regulation of B7.1 and B7.2 in metabolic organs 
during obesity, we analyzed the mRNA expression of B7.1 and B7.2 in livers and 
gonadal AT from male WT mice fed a normal diet (ND) or a high-fat diet (HFD) for 
up to 18 weeks. Although there was no change in the expression of B7.1 or B7.2 in 
the total liver, we found that B7.2 was significantly upregulated in the fraction of 
isolated non-parenchymal cells (NPC), which largely represents the immune cell 
compartment of the liver (suppl.fig.1a). Moreover, both molecules were upregulated 
in the AT upon HFD, as well as in the stromal vascular fraction (SVF) of the AT, 
which contains immune cells that are resident or have infiltrated in the course of DIO 
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into the AT (suppl.fig.1b). These findings indicate that the expression of B7.1 and 
B7.2 is elevated in metabolic organs in the course of DIO, thereby implying a possible 
role of B7.1 and B7.2-dependent co-stimulation in the regulation of obesity-associated 
inflammatory processes. 
 
B7.1-B7.2 double deficiency deteriorates obesity-related metabolic dysfunction  
Considering that the co-stimulatory molecules B7.1 and B7.2 share several 
overlapping functional properties in regulating T-cell responses(8,10), we engaged B7 
double knockout (Dko) mice, in order to study the role of B7 co-stimulation in DIO. 
Therefore, B7.1 and B7.2-sufficient- and –deficient (double knockout, Dko) male 
mice were fed a ND or a HFD. When fed a HFD, Dko mice displayed increased 
weight gain and food intake as compared to B7.1 and B7.2-sufficient (wild-type; WT) 
mice (fig.1a and suppl.Table1). Consistently, increased weight of liver and 
subcutaneous AT was observed in HFD-fed Dko mice (fig.1b). Although 
subcutaneous and gonadal AT weights were also increased in Dko mice upon ND 
feeding, no significant difference in body weight gain between ND-fed WT and Dko 
mice was observed (fig.1a,b). In addition, metabolic cage analysis showed increased 
Respiratory Exchange Ratio (RER) (suppl.fig.2) in Dko mice upon HFD. These data 
indicate decreased lipid oxidation rates in Dko mice that could account for the 
increased tissue weights in these mice via higher lipid deposition. In line with these 
results, we found increased leptin and cholesterol levels in sera from HFD-fed Dko 
mice, whereas B7 double deficiency did not affect triglyceride levels (suppl.fig.3a). 
To clarify whether the hyperphagic phenotype of the Dko mice was linked to higher 
hypothalamic inflammation, we performed gene expression analysis for immune cell 
markers and inflammatory cytokines in hypothalami isolated from HFD-fed WT and 
Dko mice (suppl.fig.3b). Hypothalamic expression of inflammatory markers did not 
differ between WT and Dko mice (suppl.fig.3b). Thus, the hyperphagic phenotype in 
Dko mice is likely due to the increased levels of leptin with accelerated development 
of leptin resistance in these mice.    
 
Consistently, obese Dko mice were more glucose intolerant as compared to WT mice, 
as assessed by a glucose tolerance test (fig.1c). In addition, an in vivo insulin 
signaling assay revealed impaired hepatic and AT insulin signaling in obese Dko 
mice, as indicated by decreased insulin-induced AKT-phosphorylation (suppl.fig.4). 
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B7.1-B7.2 double deficiency promotes diet-induced steatohepatitis  
Next, we assessed the effect of B7 double-deficiency in obesity-related hepatic 
steatosis. Oil-Red O staining, enzymatic determination of liver triglyceride content as 
well as histological analysis revealed increased fat accumulation in livers from HFD-
fed Dko mice, as compared to WT mice, accompanied by increased hepatocellular 
ballooning and histological signs of inflammation (fig.2a-e), which are key 
histological features of NASH. Consistently, the NAFLD activity score (NAS) was 
not only significantly higher in obese Dko mice as compared to WT controls (fig.2e), 
but also was >5, which correlates with the presence of NASH(15). That Dko mice 
displayed enhanced progression from hepatosteatosis to steatohepatitis was confirmed 
by significantly increased levels of Alanine transaminase (ALT), Aspartate 
transaminase (AST) and Glutamate dehydrogenase (GLDH) in the sera of HFD-fed 
Dko mice (fig.3a), thereby suggesting elevated liver cell injury in B7.1/B7.2 double 
deficiency. Similarly, HFD-fed Dko mice displayed higher levels of hepatic fibrotic 
injury as compared to the HFD-fed WT controls, as assessed by a Picric-acid Sirius 
red (Picrosirius) staining analysis (fig.3b-c). Previous studies have shown that 
increased hepatic pro-fibrotic activity is linked to enhanced hepatic stellate cell (HSC) 
proliferation and mTOR activation including the activation of the p70 S6 kinase 
(p70S6K)(16-18). To address this point, we isolated HSC from HFD-fed WT or Dko 
mice and measured HSC proliferation activity by flow cytometry for PCNA and 
p70S6K activity by ribosomal protein S6 phosphorylation (suppl.fig.5b-c). HSC from 
HFD-fed Dko mice displayed increased phosphorylation of S6 ribosomal protein, 
suggesting enhanced activation status and pro-fibrotic activity of HSC in B7-
deficiency. In contrast, no difference in PCNA staining was observed.  
 
In concordance with these data, qPCR analysis showed significantly elevated 
expression of the lipogenic transcription factors SREBP1c and CHREBP and a 
tendency for increased expression of the lipogenic enzyme FAS and the fatty acid 
transporter CD36 (fig.3d) in Dko mice in DIO. Moreover, the increased expression of 
glucokinase and of the glucose transporter 2 (GLUT2) in the livers of Dko mice 
(fig.3d) in DIO is in keeping with the increased RER in B7.1/B7.2-double deficiency, 
as observed in the metabolic cage analysis (suppl.fig.2). Furthermore, the mRNA 
levels of PGC1alpha and Glut4, which are important for glucose transport in stellate 
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cells and thereby crucial for NASH-related fibrotic activity, were upregulated in livers 
from obese Dko mice (fig.3d). These data indicate greater carbohydrate utilization, 
enhanced lipid deposition and accelerated NASH development in the liver of Dko 
mice in DIO.  
 
Given the importance of inflammation in the progression of steatosis to NASH, we 
analyzed hepatic inflammation in Dko and WT mice upon DIO. In addition to 
increased immune cell infiltration in livers of HFD-fed Dko mice, as assessed by 
histological evaluation (fig.2e), qPCR analysis showed increased expression of IL-1b 
and IL-6, although the latter did not reach significance (fig.3d).  
 
Activated Kupffer cells, as well as Treg cells are important immune cells regulating 
development of NASH in an opposite fashion(4,19,20). To provide a conclusive 
picture about the enhanced liver inflammation in Dko mice, NPC from livers of WT 
and Dko mice were isolated and analyzed by flow cytometry. Dko mice displayed 
dramatically reduced numbers of Tregs in liver, when fed not only a HFD but also a 
ND (fig.4a). We also found reduced numbers of Treg cells in the blood, lymph node 
and spleen of Dko mice (suppl.fig.4a), but not altered numbers of CD4+ and CD8+ T 
cells (data not shown), as compared to WT mice, consistent with previous reports(11). 
This intrinsic reduction of Tregs in Dko mice explains the decreased numbers of 
hepatic Tregs in these mice even when fed a ND. In contrast, activated Kupffer cells 
(defined as F4/80+CD11b+ cells)(19), as well as dendritic cells (defined as CD11c+ 
cells)(21) were increased in livers from HFD-fed Dko mice, as compared to B7-
sufficient mice (fig.4b,c). Concomitant with the FACS analysis data, gene expression 
analysis of non-parenchymal cells from WT and Dko mice showed increased 
expression of IL-6 and a tendency to higher levels of TNF (fig.4d). These 
observations suggest that higher inflammation in the livers of HFD-fed Dko mice, 
likely due to the reduced amounts of Tregs, contributes to increased hepatic steatosis 
and progression to NASH under obesity-induced conditions. Together, B7 double-
deficiency deteriorates obesity-related hepatic steatosis and accelerates progression to 
hepatosteatitis.   
 
Increased AT inflammation in Dko mice upon HFD 
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Increased AT inflammation has also been linked with obesity-related metabolic 
dysregulation and glucose intolerance(1,2,22). Since we found deteriorated glucose 
tolerance in obese Dko mice (fig.1c), we next examined AT inflammation. Flow 
cytometry analysis revealed decreased Treg populations in both subcutaneous and 
gonadal AT of HFD-fed B7-deficient mice (fig.5a). Interestingly, CD4+ and CD8+ T 
cells were reduced in both depots of white AT (fig.5b), implicating impaired T cell 
activation due to the absence of B7 co-stimulation. Despite reduced numbers of CD4+ 
and CD8+ T cells in the AT of Dko mice the decrease in Tregs in these mice rather 
prevailed to mediate a proinflammatory environment in the obese AT of these mice. 
In particular, increased M1 macrophages (defined as F4/80+CD11c+CD206-) were 
observed in both types of white AT in B7.1/B7.2-deficiency (fig.5d), whereas total 
macrophages (F4/80+CD11b+) were insignificantly higher in the AT of obese Dko 
mice (fig.5c). These data suggest that Dko have enhanced AT inflammation not 
necessarily due to increased macrophage accumulation but due to enhanced 
macrophage activation and polarization to the pro-inflammatory M1 phenotype, 
which is well in keeping with the dramatic reduction of Tregs in the AT of Dko mice. 
Further supporting this notion, gene expression of IL-6 was significantly increased in 
Dko mice, whereas the elevation of TNF and IL-12 mRNA in the gonadal AT of Dko 
mice almost reached significance (fig.5e). Taken together, B7.1/B7.2 double 
deficiency resulted in enhanced AT inflammation.  
 
To further verify that Dko mice constitute an environment that promotes classical 
activation of macrophages (M1-polarization), we analyzed the inflammatory profile of 
thioglycollate-elicited peritoneal macrophages from WT and Dko mice by flow 
cytometry and qPCR. Remarkably, Dko thioglycollate-elicited macrophages had an 
M1-skewed phenotype, as observed by increased expression of iNOS, IL-6, reduced 
expression of CD206 and decreased percentage of CD206+ cells (suppl.fig6). 
Therefore, classical activation of macrophages in Dko mice likely due to the dramatic 
reduction of Tregs, seems to be an additional factor for the exacerbation of obesity-
related inflammation in metabolic tissues of these mice. 
 
Adoptive transfer of Treg cells does not improve NASH and metabolic 
dysregulation in a B7-lacking environment 
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Our data so far indicated that deterioration of NASH and metabolic imbalance in Dko 
mice was associated with a dramatic decrease of Treg cells in these mice. A previous 
study has suggested that adoptive transfer of Tregs is capable of reversing obesity-
related metabolic dysfunction(23). On the other hand, Tregs become highly apoptotic 
in a B7-lacking environment(24,25). To address whether the metabolic phenotype of 
Dko mice can be reversed by wild-type Tregs, Dko mice on DIO received weekly 
injections of isolated wild-type CD4+CD25+Tregs or control injections from the 5
th
 
week of feeding for 6 consecutive weeks. Adoptive transfer of Tregs into Dko mice 
failed to reverse the metabolic phenotype of Dko mice as assessed by glucose 
tolerance tests (suppl.fig.7). Moreover, no difference in NASH development was 
observed in livers from Dko mice after adoptive transfer with Tregs, as compared to 
control (suppl.fig.7). Liver gene expression analysis confirmed these data by showing 
no difference in lipogenesis- or inflammation-related genes in livers from the two 
groups of mice (suppl.fig.7). Consistently, flow cytometry analysis of the non-
panechymal cells did not show any significant differences in hepatic and splenic Treg 
populations between Dko mice that received Tregs or control-treated mice (data not 
shown). The absence of any increase in Treg populations / numbers between Dko 
control-treated and Dko Treg-injected mice is in line with the fact that the B7-lacking 
environment is highly pro-apoptotic for Tregs(24,25), thereby explaining that wild-
type Tregs fail to reverse NASH and metabolic deterioration in Dko mice.   
 
Blocking both B7.1 and B7.2 in vivo improves obesity-related metabolic 
dysfunction 
B7.1/B7.2 co-stimulatory molecules are important in activation of T cells, promoting 
inflammation in several conditions(8). Interestingly, our findings so far suggested that 
Dko mice, despite having reduced T cell activation (fig.5), rather represented a 
proinflammatory environment in the course of DIO, associated with reduced Treg 
numbers. Thereby Dko mice displayed metabolic dysregulation in DIO, including 
elevated glucose intolerance and enhanced progression to hepatosteatitis. We 
therefore hypothesized that the reduction of Tregs in Dko is responsible for skewing 
the system towards enhanced inflammation in DIO. However, adoptive transfer of 
wild-type Tregs did not reverse the development of NASH and metabolic 
dysregulation in Dko mice, most likely due to increased apoptosis of Treg cells in a 
B7-lacking environment(24,25). In order to elucidate the role of B7 co-stimulation 
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itself for obesity-related metabolic dysregulation in a normal, non-Treg lacking 
environment, we performed DIO in WT mice in the presence or absence of blocking 
antibodies to B7. Moreover, to determine whether B7.1 or B7.2 have distinct 
functions in DIO-related inflammation and metabolic changes, we treated HFD-fed 
WT mice either with anti-B7.1 or with anti-B7.2 or with the combination thereof. 
Mice were fed a HFD for a total of 16 weeks and injected with antibodies or isotype 
controls (twice per week) starting at week 4 of feeding. Interestingly, treatment of WT 
mice in DIO with anti-B7.1 or anti-B7.2 alone did not mediate any alterations in 
weight gain and importantly in glucose tolerance, as compared to HFD-fed isotype 
control-treated mice (suppl.fig.8). However, mice injected with the combination of 
both anti-B7.1 and anti-B7.2 antibodies displayed improved glucose tolerance and 
insulin sensitivity, as well as increased insulin-induced hepatic AKT-phosphorylation 
(suppl.fig.9), as compared to the isotype control-treated HFD-fed WT mice, although 
no differences in weight gain or in the weight of metabolic tissues were observed 
(fig.6a-c). Consistently, no difference in food intake, energy expenditure or 
Respiratory Exchange Ratio (RER) was observed between the two groups of mice, 
when metabolic cage analysis was performed (suppl.fig.10). As expected, exogenous 
administration of anti-B7.1 and anti-B7.2 antibodies did not affect the numbers of 
Tregs in mice (suppl.fig.11).  
 
We then continued to explore whether improved glucose tolerance and insulin 
sensitivity due to concomitant B7.1 and B7.2 blockade in mice were also reflected by 
changes in AT inflammation or liver steatosis. IL-1b and IL-6 were reduced in the AT 
of anti-B7.1/anti-B7.2 injected mice as revealed by qPCR analysis (fig.6d). These 
data imply that blocking of cell-cell interactions by the antibody-mediated inhibition 
of B7 accounts for reduced AT inflammation. Furthermore, anti-B7.1/anti-B7.2 
injected mice in DIO displayed reduced hepatic steatosis and ballooning of 
hepatocytes as well as reduced NAFLD activity score (fig.7a,b), while the fibro-
inflammatory injury was ameliorated in these mice, as revealed by Picrosirius staining 
analysis (Fig.7c-d). The reduced lipid accumulation and liver damage phenotype of 
the anti-B7.1/anti-B7.2 injected mice was confirmed by qPCR analysis that displayed 
decreased levels of the fatty acid transporter CD36 and also of the steatosis-related 
growth factor TGF-beta(26) (fig.8a). As in lymphoid organs and the AT (suppl.fig.11 
and data not shown), Treg cell population in the liver was also not affected by 
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B7.1/B7.2 blockade, as assessed by foxp3 gene expression (fig.8a). Interestingly, 
inflammatory markers such as IL-6 and IL-1b were significantly decreased in mice 
injected with anti-B7.1/anti-B7.2 (fig.8a).  
 
Decreased inflammatory activation by B7.1/B7.2 blockade could be due to inhibition 
of the communication of hepatocytes and/or antigen-presenting cells with T cells 
within the liver micro-environment. To verify this hypothesis, we simulated the liver 
environment under obese conditions in vitro and performed hepatocyte-NPC co-
cultures in the presence of palmitate, while cell-cell interactions were blocked with 
the combination of anti-B7.1 and anti-B7.2. Reduced IL-6, IL-1b and TNF were 
detected in supernatants of co-cultures when anti-B7.1 and anti-B7.2 were applied, as 
compared to the isotype control treated co-cultures (fig.8b). These data imply that B7 
co-stimulation could mediate intercellular communication between hepatocytes and 
immune cells, thereby potentially triggering hepatic inflammation in DIO. 
 
Taken together, concomitant blockade of B7.1 and B7.2 in the presence of Tregs 
improves glucose tolerance, insulin sensitivity, hepatic steatosis as well as AT and 
liver inflammation, thus suggesting B7 co-stimulation itself contributes to obesity-
related inflammation and metabolic dysregulation.   
 
DISCUSSION 
Co-stimulatory molecules play a major role in the intercellular communication of 
adaptive immune cells with antigen-presenting cells, innate immune cells or 
parenchymal cells(8,27,28). A plethora of cell-cell interactions take place in liver and 
AT in the course of obesity, regulating inflammation and thereby the development of 
steatohepatitis and insulin resistance(1,2,20,29,30). Here, we identified B7-dependent 
co-stimulation as a major regulator of obesity-related inflammatory processes and 
metabolic dysregulation(1,2). B7.1/B7.2 double-deficiency exacerbated the 
development of NASH and metabolic dysregulation upon DIO, a phenotype attributed 
to the absence of Treg cells in liver and AT of these mice. In contrast, antibody-
mediated blockade of B7 interactions under conditions, where regulatory T cells are 
present, protected mice from the development of obesity-related pathologies and 
especially NASH.  
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In the course of obesity, Dko mice displayed a deteriorated metabolic phenotype. 
Importantly, Dko mice displayed increased hepatic steatosis, hepatocellular 
ballooning, deteriorated hepatic insulin signalling and enhanced progression to 
hepatosteatitis/NASH. Inflammation constitutes the second hit in the prevailing 2-hit 
theory for the pathogenesis of NASH, in which lipid accumulation is followed by a 
second stimulus that triggers the evolution of steatosis to steatitis(4,19,20). Activated 
Kupffer cells in the liver mediate obesity-related liver inflammation, mainly by 
producing cytokines such as TNF, IL-6 and IL-1b(20,29,31). Likewise, the reduction 
of Tregs and/or of the anti-inflammatory cytokine IL-10 in the liver promotes liver 
inflammation(4,32). The pro-inflammatory hepatic features associated with NASH 
development were exacerbated in B7-double deficiency. The dramatic decrease in 
Treg numbers in the blood and lymphoid tissues of Dko mice due to the absolute 
requirement of B7 co-stimulation for Treg survival and proliferation(11,33) resulted 
in the absence of Tregs from metabolic organs (liver, AT). The B7-deficient 
environment is “toxic“ to Tregs, as was evidenced by the failure of adoptive transfer 
of wild-type Tregs to reverse the metabolic phenotype of Dko mice, as compared to 
wild-type mice in DIO(23). Consistent with increased Treg apoptosis in B7-negative 
environment(24,25), no increase in Treg numbers was found in the lymphoid and 
metabolic organs of B7-deficient mice upon adoptive Treg transfer. Together, due to 
the absence of Tregs, deficiency of B7 co-stimulation promoted a pro-inflammatory 
environment in the liver with increased numbers of activated Kupffer cells and 
enhanced proinflammatory gene expression. Our findings are in line with those of Ma 
et al. that demonstrated a connection between Treg reduction and the development of 
liver steatosis under obese conditions(4). Together, the early and exacerbated NASH 
development in B7.1/B7.2 double deficiency also indicates that Dko may represent a 
feasible mouse model for studying NASH in future studies. 
 
Consistently, HFD-fed Dko mice displayed higher levels of hepatic fibro-
inflammatory injury. Isolated HSC from Dko mice displayed increased 
phosphorylation of S6 ribosomal protein, suggesting enhanced pro-fibrotic 
activity(16-18), whereas we did not find significantly elevated HSC proliferation due 
to B7-deficiency. The latter could be due to the fact that only one time point (15 
weeks on HFD) was used for proliferation analysis of isolated HSC. A detailed time 
kinetic analysis comparing stellate cell proliferation and activation in WT and Dko 
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mice on a HFD and ND for different time points would be necessary to fully address 
this issue in a future study.   
 
Accumulating evidence underlines the role of leptin in NASH development mainly 
via immune cell activation in NAFLD(34,35). The increased levels of leptin 
accompanied by reduced Treg numbers in B7 Dko mice are in line with the already 
established reciprocal relationship between leptin levels and Treg proliferation(36-
38). Thus, in our study, the enhanced leptin levels in B7 Dko mice likely contributed 
to the progression to steatohepatitis in these mice.   
 
In addition to hepatosteatitis, metabolic parameters such as glucose tolerance or 
insulin signalling were worse in B7-deficient mice. Metabolic deterioration in B7-
deficient mice was associated with significantly higher AT inflammation, as assessed 
by the enhanced M1 polarization of macrophages in the AT and increased expression 
of pro-inflammatory cytokines, such as TNF and IL-6 that act to mediate AT insulin 
resistance(2,31). Interestingly, the AT environment in Dko mice was pro-
inflammatory despite reduced accumulation of effector T cells (CD4+ and CD8+ 
cells), as B7 co-stimulation is an important effector for T cell activation. Together, 
our data suggest that, although co-stimulation is indispensable for T cell activation, 
the diminution of Tregs in metabolic organs of Dko is hierarchically the driving force 
triggering liver and AT inflammation in DIO, thereby leading to hepatosteatitis and 
glucose intolerance.  
 
To further support the notion that the dramatic reduction in Tregs accounted for 
aggravation of steatohepatitis and metabolic deterioration in Dko mice and could 
over-ride any beneficial effects of disruption of B7-dependent co-stimulation, we 
blocked B7 interactions under conditions where Tregs were present. To this end, we 
exogenously administered anti-B7.1 and anti-B7.2 antibodies into wild-type mice in 
DIO. The use of B7 blockade was the only possible experimental approach to address 
Treg-independent functions of B7 co-stimulation in DIO, given our finding that 
adoptive transfer of wild-type Treg cells was not operative in the B7-negative 
environment, although this approach has been previously engaged to ameliorate 
obesity-related AT inflammation and metabolic dysregulation in B7-sufficient wild-
type settings(23,39). The improvement of metabolic dysregulation and reduced 
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hepatosteatosis/hepatosteatitis by concomitant antibody-mediated inhibition of both -
B7.1 and B7.2 in DIO but not by inhibiting each one alone suggests a synergistic 
action of B7.1 and B7.2 to promote obesity-related inflammation. B7 co-stimulation 
was found to mediate interactions between hepatocytes and NPC, which are important 
for the initiation and progress of inflammation in the intrahepatic environment(40). In 
particular, anti-B7.1/B7.2 blockade reduced the expression of inflammatory cytokines 
in hepatocyte-NPC co-cultures. Moreover, blocking B7 interactions alleviated AT 
inflammation, in keeping with recent studies that identified adipocytes as antigen-
presenting cells(41). A previous study has manipulated the B7/CD28/CTLA-4 co-
stimulation by using CTLA-4-Ig; this treatment did not significantly improve 
steatohepatitis or metabolic dysregulation in DIO(42). While our manuscript was in 
preparation, a study appeared showing that B7-double deficiency is linked to 
enhanced AT inflammation and insulin resistance; in contrast, this study did not 
report the hepatic phenotype of B7-double deficiency(43). Based on their findings 
with Dko mice, these authors concluded that B7 co-stimulation protects from insulin 
resistance. However, our approach to block B7.1 and B7.2 in the presence of Tregs in 
WT mice uncovered that B7-costimulation in fact promotes obesity-related metabolic 
dysregulation and NASH. We therefore conclude that intercellular B7 co-stimulatory 
interactions contribute to the exacerbation of inflammation in liver and AT during 
DIO. However, in Dko mice the absence of Tregs simply masked any beneficial anti-
inflammatory effects that could derive from inactivation of B7 co-stimulation.  
 
In conclusion, the present study identified that B7.1 and B7.2 co-stimulation plays 
important roles in obesity-related inflammation, glucose intolerance and 
hepatosteatitis. Genetic inactivation and antibody inhibition of CD80/CD86 co-
stimulatory molecules affect obesity-related hepatosteatitis and metabolic 
dysregulation in an opposite fashion, which is orchestrated by the numbers and 
function of Tregs. Our findings not only underline the importance of Tregs as a 
master regulator of obesity-driven liver inflammation, but also indicate that inhibition 
of B7 co-stimulation may provide a novel platform for potential therapeutic 
manipulation for the prevention of NASH and likely other obesity-related 
complications.  
 
ACKNOWLEDGEMENTS 
Page 16 of 54
Hepatology
Hepatology
16 
 
The authors would like to thank Maria Moisidou, Sylvia Grossklaus, Janine Gebler, 
Bettina Gercken, Marta Prucnal and Christine Mund for technical assistance.  
 
References 
1. Chatzigeorgiou A, Karalis KP, Bornstein SR, Chavakis T. Lymphocytes in 
obesity-related adipose tissue inflammation. Diabetologia 2012;55:2583-2592. 
2. Chmelar J, Chung KJ, Chavakis T. The role of innate immune cells in obese 
adipose tissue inflammation and development of insulin resistance. Thromb Haemost 
2013;109:399-406. 
3. Cusi K. Role of obesity and lipotoxicity in the development of nonalcoholic 
steatohepatitis: pathophysiology and clinical implications. Gastroenterology 
2012;142:711-725 e716. 
4. Ma X, Hua J, Mohamood AR, Hamad AR, Ravi R, Li Z. A high-fat diet and 
regulatory T cells influence susceptibility to endotoxin-induced liver injury. 
Hepatology 2007;46:1519-1529. 
5. Winer S, Chan Y, Paltser G, Truong D, Tsui H, Bahrami J, Dorfman R, et al. 
Normalization of obesity-associated insulin resistance through immunotherapy. Nat 
Med 2009;15:921-929. 
6. Duval C, Thissen U, Keshtkar S, Accart B, Stienstra R, Boekschoten MV, 
Roskams T, et al. Adipose tissue dysfunction signals progression of hepatic steatosis 
towards nonalcoholic steatohepatitis in C57BL/6 mice. Diabetes 2010;59:3181-3191. 
7. Schaffler A, Scholmerich J, Buchler C. Mechanisms of disease: 
adipocytokines and visceral adipose tissue--emerging role in nonalcoholic fatty liver 
disease. Nat Clin Pract Gastroenterol Hepatol 2005;2:273-280. 
8. Ceeraz S, Nowak EC, Noelle RJ. B7 family checkpoint regulators in immune 
regulation and disease. Trends Immunol 2013. 
9. Buhlmann JE, Elkin SK, Sharpe AH. A role for the B7-1/B7-2:CD28/CTLA-4 
pathway during negative selection. J Immunol 2003;170:5421-5428. 
10. Borriello F, Sethna MP, Boyd SD, Schweitzer AN, Tivol EA, Jacoby D, 
Strom TB, et al. B7-1 and B7-2 have overlapping, critical roles in immunoglobulin 
class switching and germinal center formation. Immunity 1997;6:303-313. 
11. Zeng M, Guinet E, Nouri-Shirazi M. B7-1 and B7-2 differentially control 
peripheral homeostasis of CD4(+)CD25(+)Foxp3(+) regulatory T cells. Transpl 
Immunol 2009;20:171-179. 
12. Buono C, Pang H, Uchida Y, Libby P, Sharpe AH, Lichtman AH. B7-1/B7-2 
costimulation regulates plaque antigen-specific T-cell responses and atherogenesis in 
low-density lipoprotein receptor-deficient mice. Circulation 2004;109:2009-2015. 
13. Chatzigeorgiou A, Seijkens T, Zarzycka B, Engel D, Poggi M, van den Berg S, 
van den Berg S, et al. Blocking CD40-TRAF6 signaling is a therapeutic target in 
obesity-associated insulin resistance. Proc Natl Acad Sci U S A 2014;111:2686-2691. 
14. Poggi M, Engel D, Christ A, Beckers L, Wijnands E, Boon L, Driessen A, et 
al. CD40L deficiency ameliorates adipose tissue inflammation and metabolic 
manifestations of obesity in mice. Arterioscler Thromb Vasc Biol 2011;31:2251-2260. 
15. Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW, 
Ferrell LD, et al. Design and validation of a histological scoring system for 
nonalcoholic fatty liver disease. Hepatology 2005;41:1313-1321. 
Page 17 of 54
Hepatology
Hepatology
17 
 
16. Caligiuri A, Bertolani C, Guerra CT, Aleffi S, Galastri S, Trappoliere M, 
Vizzutti F, et al. Adenosine monophosphate-activated protein kinase modulates the 
activated phenotype of hepatic stellate cells. Hepatology 2008;47:668-676. 
17. Xu WH, Hu HG, Tian Y, Wang SZ, Li J, Li JZ, Deng X, et al. Bioactive 
compound reveals a novel function for ribosomal protein S5 in hepatic stellate cell 
activation and hepatic fibrosis. Hepatology 2014. 
18. Wang Y, Gao J, Zhang D, Zhang J, Ma J, Jiang H. New insights into the 
antifibrotic effects of sorafenib on hepatic stellate cells and liver fibrosis. J Hepatol 
2010;53:132-144. 
19. Tosello-Trampont AC, Landes SG, Nguyen V, Novobrantseva TI, Hahn YS. 
Kuppfer cells trigger nonalcoholic steatohepatitis development in diet-induced mouse 
model through tumor necrosis factor-alpha production. J Biol Chem 2012;287:40161-
40172. 
20. Stienstra R, Saudale F, Duval C, Keshtkar S, Groener JE, van Rooijen N, 
Staels B, et al. Kupffer cells promote hepatic steatosis via interleukin-1beta-dependent 
suppression of peroxisome proliferator-activated receptor alpha activity. Hepatology 
2010;51:511-522. 
21. Connolly MK, Bedrosian AS, Mallen-St Clair J, Mitchell AP, Ibrahim J, 
Stroud A, Pachter HL, et al. In liver fibrosis, dendritic cells govern hepatic 
inflammation in mice via TNF-alpha. J Clin Invest 2009;119:3213-3225. 
22. Lumeng CN, Bodzin JL, Saltiel AR. Obesity induces a phenotypic switch in 
adipose tissue macrophage polarization. J Clin Invest 2007;117:175-184. 
23. Eller K, Kirsch A, Wolf AM, Sopper S, Tagwerker A, Stanzl U, Wolf D, et al. 
Potential role of regulatory T cells in reversing obesity-linked insulin resistance and 
diabetic nephropathy. Diabetes 2011;60:2954-2962. 
24. Bar-On L, Birnberg T, Kim KW, Jung S. Dendritic cell-restricted CD80/86 
deficiency results in peripheral regulatory T-cell reduction but is not associated with 
lymphocyte hyperactivation. Eur J Immunol 2011;41:291-298. 
25. Zou T, Caton AJ, Koretzky GA, Kambayashi T. Dendritic cells induce 
regulatory T cell proliferation through antigen-dependent and -independent 
interactions. J Immunol 2010;185:2790-2799. 
26. Yadav H, Quijano C, Kamaraju AK, Gavrilova O, Malek R, Chen W, Zerfas P, 
et al. Protection from obesity and diabetes by blockade of TGF-beta/Smad3 signaling. 
Cell Metab 2011;14:67-79. 
27. Chen L. Co-inhibitory molecules of the B7-CD28 family in the control of T-
cell immunity. Nat Rev Immunol 2004;4:336-347. 
28. Chatzigeorgiou A, Lyberi M, Chatzilymperis G, Nezos A, Kamper E. 
CD40/CD40L signaling and its implication in health and disease. Biofactors 
2009;35:474-483. 
29. De Taeye BM, Novitskaya T, McGuinness OP, Gleaves L, Medda M, 
Covington JW, Vaughan DE. Macrophage TNF-alpha contributes to insulin resistance 
and hepatic steatosis in diet-induced obesity. Am J Physiol Endocrinol Metab 
2007;293:E713-725. 
30. Tang Y, Bian Z, Zhao L, Liu Y, Liang S, Wang Q, Han X, et al. Interleukin-17 
exacerbates hepatic steatosis and inflammation in non-alcoholic fatty liver disease. 
Clin Exp Immunol 2011;166:281-290. 
31. Chawla A, Nguyen KD, Goh YP. Macrophage-mediated inflammation in 
metabolic disease. Nat Rev Immunol 2011;11:738-749. 
Page 18 of 54
Hepatology
Hepatology
18 
 
32. Feuerer M, Herrero L, Cipolletta D, Naaz A, Wong J, Nayer A, Lee J, et al. 
Lean, but not obese, fat is enriched for a unique population of regulatory T cells that 
affect metabolic parameters. Nat Med 2009;15:930-939. 
33. Bour-Jordan H, Bluestone JA. Regulating the regulators: costimulatory signals 
control the homeostasis and function of regulatory T cells. Immunol Rev 
2009;229:41-66. 
34. Chatterjee S, Ganini D, Tokar EJ, Kumar A, Das S, Corbett J, Kadiiska MB, et 
al. Leptin is key to peroxynitrite-mediated oxidative stress and Kupffer cell activation 
in experimental non-alcoholic steatohepatitis. J Hepatol 2013;58:778-784. 
35. Procaccini C, Galgani M, De Rosa V, Carbone F, La Rocca C, Ranucci G, 
Iorio R, et al. Leptin: the prototypic adipocytokine and its role in NAFLD. Curr 
Pharm Des 2010;16:1902-1912. 
36. De Rosa V, Procaccini C, Cali G, Pirozzi G, Fontana S, Zappacosta S, La 
Cava A, et al. A key role of leptin in the control of regulatory T cell proliferation. 
Immunity 2007;26:241-255. 
37. Procaccini C, De Rosa V, Galgani M, Abanni L, Cali G, Porcellini A, Carbone 
F, et al. An oscillatory switch in mTOR kinase activity sets regulatory T cell 
responsiveness. Immunity 2010;33:929-941. 
38. Matarese G, Procaccini C, De Rosa V, Horvath TL, La Cava A. Regulatory T 
cells in obesity: the leptin connection. Trends Mol Med 2010;16:247-256. 
39. Deiuliis J, Shah Z, Shah N, Needleman B, Mikami D, Narula V, Perry K, et al. 
Visceral adipose inflammation in obesity is associated with critical alterations in 
tregulatory cell numbers. PLoS One 2011;6:e16376. 
40. Scott MJ, Liu S, Su GL, Vodovotz Y, Billiar TR. Hepatocytes enhance effects 
of lipopolysaccharide on liver nonparenchymal cells through close cell interactions. 
Shock 2005;23:453-458. 
41. Hruskova Z, Biswas SK. A new "immunological" role for adipocytes in 
obesity. Cell Metab 2013;17:315-317. 
42. Montes VN, Turner MS, Subramanian S, Ding Y, Hayden-Ledbetter M, Slater 
S, Goodspeed L, et al. T cell activation inhibitors reduce CD8+ T cell and pro-
inflammatory macrophage accumulation in adipose tissue of obese mice. PLoS One 
2013;8:e67709. 
43. Zhong J, Rao X, Braunstein Z, Taylor A, Narula V, Hazey J, Mikami D, et al. 
T-cell costimulation protects obesity-induced adipose inflammation and insulin 
resistance. Diabetes 2013;63:1289-1302. 
 
 
 
 
Page 19 of 54
Hepatology
Hepatology
19 
 
Legends to figures 
Figure 1 
Metabolic profile of B7.1-B7.2 Dko mice 
Wild type (WT) and Dko male mice were fed with normal-fat (ND) or high-fat diet 
(HFD). A) Body weight gain of WT and Dko mice on ND or HFD in grams. B) 
Subcutaneous AT, gonadal AT and liver weights of WT and Dko mice after 18 weeks 
on ND or HFD are displayed as percentage of total body weight. C) Glucose tolerance 
test in WT and Dko mice fed a ND or HFD for 17 weeks was performed as described 
under Materials and Methods. Data are mean±SEM; n=10-19; *p<0.05 (comparisons 
between WT and Dko mice fed the same diet). 
 
Figure 2 
Increased hepatosteatitis in Dko mice upon HFD 
A) Oil red O staining in liver cryosections from WT and Dko mice fed a ND or HFD 
for 18 weeks is shown (A) (x100 magnification). B) The Oil-Red O positive area was 
evaluated by using the ImageJ software and expressed as percentage of the total area 
(n=at least 4). Data are mean±SEM, *p<0.05 for comparison between WT and Dko 
mice fed the same diet. C) Liver triglyceride content was quantified in WT and Dko 
mice fed a ND or HFD for 18 weeks (n=at least 5 for ND and n=at least 14 for HFD). 
Data are mean±SEM, *p<0.05 for comparison between WT and Dko mice fed the 
same diet. D) Representative H&E staining in liver paraffin sections from WT and 
Dko mice fed a HFD for 18 weeks is shown (x100 magnification). E) Histological 
scoring of NASH in liver sections from WT and Dko mice fed a HFD for 18 weeks 
was done as described under Materials and Methods. Steatosis and inflammation were 
scored using a 0 to 3 scale while ballooning by using a 0 to 2 scale according to the 
NASH-CRN Committee scoring system (n=at least 6). The NAFLD activity score 
(NAS) is defined as the sum of steatosis, lobular inflammation and ballooning. Data 
are mean±SEM, *p<0.05.  
 
Figure 3 
Increased liver damage in Dko mice upon HFD 
A) Serum alanine transaminase (ALT), aspartate transaminase (AST) and glutamate 
dehydrogenase (GLDH) activities in sera from WT and Dko mice fed a HFD for 18 
weeks (n=at least 10). B) Representative Picrosirius staining in liver sections from 
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WT and Dko mice fed a HFD for 18 weeks (x100 magnification). C) The Picrosirius 
positive area was evaluated by using the ImageJ software and expressed as percentage 
of the total area (n=6). D) Liver gene expression analysis from WT or Dko mice fed a 
HFD for 18 weeks. Shown are mRNA levels of genes related to lipogenesis 
(SREBP1C, Sterol Regulatory Element-Binding Protein; CHREBP, Carbohydrate-
responsive element-binding protein; FAS, fatty acid synthase), lipid uptake (CD36), 
glucose uptake and metabolism (GLUT2, Glucose transporter 2; GCK, glucokinase, 
GLUT4, Glucose transporter 4; PPAR-γ, Peroxisome proliferator-activated receptor 
gamma; PGC1a, PPAR-γ coactivator 1-alpha) and inflammation (IL-6, IL-1b). The 
mRNA expression was normalized against 18S and the gene expression of livers from 
WT mice under HFD was set as 1 (n=6). Data are mean±SEM, *p<0.05. 
 
Figure 4 
Increased hepatic inflammation in Dko mice upon HFD 
A-C) WT or Dko male mice were fed a ND or HFD for 14 weeks and non-
parenchymal cells (NPC) were isolated from livers and analyzed by flow cytometry. 
A) Treg cells (defined as CD4+CD25+Foxp3+); B) Kupffer cells (defined as 
CD11b+F4/80+); and C) dendritic cells (defined as CD11c+) are shown. Cells were 
expressed as absolute cell number per liver. Treg cells were additionally expressed as 
percentage of CD4 positive cells (n= 5). Data are mean±SEM, *p<0.05, for 
comparison between WT and Dko mice fed the same diet. D) qPCR analysis for TNF, 
IL-6 and MCP-1 in NPC isolated from WT or Dko male mice fed a HFD for 14 weeks 
(n= 5 mice). The mRNA expression was normalized against actin and the gene 
expression of non-parenchymal cells from WT HFD was set as 1. Data are 
mean±SEM, *p<0.05. 
 
Figure 5 
B7 double deficiency aggravates AT inflammation 
SVF (stromal vascular fraction) cells from subcutaneous (sub) or gonadal (gon) AT of 
WT or Dko male mice fed a HFD for 18 weeks were isolated and analyzed by flow 
cytometry. A-D) Treg cells (defined as CD4+CD25+Foxp3+) (A), CD3+CD4+ or 
CD3+CD8+ lymphocytes (B), macrophages (characterized as CD11b+F4/80+) (C) 
and M1-macrophages (defined as F4/80+CD11c+CD206-) (D) were detected. Cells 
were expressed as cells per gram of tissue. Treg cells were additionally expressed as 
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percentage of CD4 positive cells (n=at least 7). Data are mean±SEM, *p<0.05. E) 
Gonadal AT gene expression analysis from WT or Dko mice fed a ND or HFD for 18 
weeks. The mRNA levels of TNF, IL-6, IL-12 and MCP-1 are shown. 18S was used 
for normalization of mRNA expression and the gene expression of WT ND was set as 
1. n= 5/group for ND and n= 7/group for HFD. Data are mean±SEM, *p<0.05 for 
comparison between WT and Dko mice fed the same diet. 
 
Figure 6 
Blocking B7.1 and B7.2 with antibodies in vivo improved obesity-related 
metabolic dysregulation 
WT male mice were fed a HFD for a total of 16 wks and received a combination of 
anti-B7.1 and anti-B7.2 antibodies (anti-B7.1/B7.2 WT mice) or isotype controls 
(CTRL WT mice) starting at week 4 of feeding (200µg of each antibody or isotype 
control were injected intraperitoneally per mouse, twice per week). A) Body weight of 
HFD-fed mice treated with antibodies or isotype controls is displayed in grams. B) 
Glucose and insulin tolerance tests were performed in weeks 15 and 16 of feeding, 
respectively, as described under Materials and Methods. C) Subcutaneous and 
gonadal AT and liver weight of WT mice treated with anti-B7.1/B7.2 or isotype 
control antibodies are displayed in grams. Data are mean±SEM; (n= at least 8); 
*p<0.05.  D) Gene expression analysis of inflammatory genes and leptin was 
performed in gonadal AT from the two groups of mice. The mRNA expression was 
normalized against 18S and the gene expression of isotype control-injected mice was 
set as 1 (n=at least 6). Data are mean ± SEM, *p<0.05. 
 
Figure 7 
Anti-B7.1 and B7.2 treatment improves obesity-related liver damage 
WT male mice were fed a HFD for a total of 16 wks, receiving a combination of anti-
B7.1 and anti-B7.2 antibodies (anti-B7.1/B7.2 WT mice) or isotype controls (CTRL 
WT mice) starting at week 4 of feeding (200µg of each antibody or isotype control 
were injected intraperitoneally per mouse, twice per week). A) Representative H&E 
staining in liver paraffin sections from CTRL WT and anti-B7.1/B7.2 WT mice (x100 
magnification). B) Histological scoring of NASH in liver sections from CTRL WT 
and anti-B7.1/B7.2 WT mice was done as described under Materials and Methods. 
Steatosis and inflammation were scored using a 0 to 3 scale, while ballooning by 
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using a 0 to 2 scale. The NAFLD activity score (NAS) represents the sum of steatosis, 
lobular inflammation and ballooning. n= 6. C) Representative Picrosirius staining in 
liver sections from CTRL WT and anti-B7.1/B7.2 WT mice is shown (x100 
magnification). D) The Picrosirius positive area was evaluated by using the ImageJ 
software and expressed as percentage of the total area (n=6). Data are mean±SEM, 
*p<0.05. 
 
 
Figure 8 
Anti-B7.1 and B7.2 treatment improved liver inflammation 
A) WT male mice were fed a HFD for a total of 16 wks and received from week 4 of 
the feeding a combination of anti-B7.1 and anti-B7.2 antibodies or isotype controls 
(200µg of each antibody or isotype control were injected intraperitoneally per mouse, 
twice per week). The mRNA levels of lipid accumulation-related genes (CD36, TGF-
b), inflammatory genes (IL-6, TNF, IL-1b) and of the transcription factor FOXP3 
were analyzed by qPCR. 18S expression was used for normalization of mRNA 
expression and the gene expression of CTRL-WT mice was set as 1 (n= at least 7). 
Data are mean±SEM, *p<0.05. B) Hepatocytes and Non-Parenchymal Cells (NPC) 
were isolated from livers of WT mice and co-cultured for 24 hours with 500µmol/l 
palmitate and in the presence of a combination of anti-B7.1/B7.2 antibodies or isotype 
controls as described under Materials and Methods. The levels of secreted cytokines 
were detected in supernatants by ELISA (n= at least 5). Data are mean±SEM, 
*p<0.05.  
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MATERIALS AND METHODS 
 
Animal studies and diets 
Mice deficient in both B7.1 and B7.2 (double knockouts, Dko) in a C57BL/6 
background, kindly provided by Dr. R. Hodes (Experimental Immunology Branch, 
NCI, NIH), were previously described (1, 2). C57BL/6 mice were used as wild-type 
controls (WT). WT and Dko mice were bred and co-housed in our facility for several 
generations. Male mice sufficient or deficient in B7.1 and B7.2 were fed a normal-fat 
diet or high-fat diet (D12450B, 10% fat or D12492, 60% fat respectively, Research 
Diets, NJ, USA) for up to 18 weeks starting at the age of 7-8 weeks. In other 
experiments, regulatory T cells were adoptively transferred into Dko mice that were 
fed a high-fat diet for a total of 12 weeks. The intraperitoneal injections of Tregs (or 
PBS as control) into Dko mice were performed once per week for 6 consecutive 
weeks, starting at week 5 of the HFD feeding; 0.75x106 Tregs were transferred per 
injection per mouse. Treg isolation for this purpose is described below under “Treg 
isolation from spleen”.  
 
Additionally, C57BL/6 mice were fed a HFD for 16 weeks and injected either with 
anti-B7.1 alone or with anti-B7.2 alone or with a combination of anti-B7.1 and anti-
B7.2 antibodies or isotypes (twice per week, 200 µg/mouse of each antibody or 
isotype, Bioceros, Utrecht, Netherlands) starting at week 4 of HFD feeding. After the 
experimental period, mice were euthanized and tissues and blood were collected and 
either processed immediately or stored in -80°C for further analysis. All animal 
experiments were performed according to the criteria outlined in the "Guide for the 
Care and Use of Laboratory Animals", published by the National Institutes of Health 
(NIH). All animal experiments were approved by the Landesdirektion Dresden, 
Germany. 
 
Metabolic tests 
Blood glucose, triglycerides and cholesterol were measured in overnight fasted mice 
by tail-vein blood sampling and by using a glucose meter device (Accu-Chek, Roche, 
Mannheim, Germany) and the Accutrend Plus system (Roche, Mannheim, Germany), 
respectively. For glucose tolerance test (GTT), overnight-fasted mice were injected i.p. 
with glucose (1g/kg). For insulin tolerance test (ITT), 5-6 h fasted mice were injected 
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i.p. with insulin (1.5U/kg, Huminsulin, Lilly, Bad Homburg, Germany). Glucose 
levels were measured in both tests at 0, 15, 30, 60, 90 and 120 minutes post injection. 
 
Metabolic cage analysis 
Mice were individually housed in metabolic cages (PhenoMaster, TSE Systems, Bad 
Homburg, Germany) with free access to water and food, maintaining a 12h:12h light-
dark cycle. A period of at least 24 hours acclimatization in the metabolic cages 
preceded initiation of the experiment and data collection. Volume of oxygen 
consumption (VO2) and carbon dioxide production (VCO2) were determined every 20 
minutes. Respiratory exchange ratio (RER) was calculated as VCO2/VO2, whereas 
energy expenditure (EE) was determined using the formula 3.941 x VO2 + 1.106 x 
VCO2 (3). Locomotion as well as food and water intakes were also monitored. Data 
were normalized with respect to body weight using ANCOVA analysis. 
 
Serum and supernatant parameters 
Mouse serum or culture supernatant parameters were measured by using 
commercially available kits. More specifically, leptin, IL-6, IL-1b and TNF were 
measured with kits from R&D. Alanine transaminase (ALT), Aspartate transaminase 
(AST) and Glutamate dehydrogenase (GLDH) were measured in sera in a Roche 
Modular P800 Analyzer.  
 
Measurement of liver triglyceride content 
Triglyceride quantification in the liver was done by using a commercially available kit 
(Abcam, Cambridge, UK). Briefly, 100mg of tissue was homogenized in 1ml of 5% 
Triton-X100 in water and the samples were then heated to 95°C and cooled to room 
temperature twice. After centrifugation, triglyceride determination in the supernatants 
was done enzymatically.  
 
In vivo insulin-induced phospho-AKT activation analysis 
The in vivo phospho-AKT signaling study was performed as described previously (4). 
Briefly, WT and DKO mice or isotype- and anti-B7.1/B7.2 treated mice fed with HFD 
were fasted overnight prior to an intraperitoneal injection of 2 U/kg insulin (Lilly). 
After 7 minutes, liver and gonadal adipose tissues were collected and snap frozen in 
Page 34 of 54
Hepatology
Hepatology
4 
 
liquid nitrogen. Cell lysates were prepared and western blot analysis was performed 
by using antibodies against phospho-AKT (phospho-AKT–Ser473, Cell Signaling, 
Germany) and total AKT (Cell Signaling, Germany). The band intensity was 
quantified by using the ImageJ software and the insulin-induced phospho-AKT was 
evaluated by normalization over total AKT signaling. 
 
Hepatocyte and non-parenchymal cell (NPC) isolation 
Isolation of hepatocytes and non-parenchymal cells (NPC) was done according to 
previously published protocols with some modifications (5-7). After systemic 
perfusion of mice, livers were excised, minced and incubated in DMEM containing 
crude collagenase and hyaluronidase (Sigma Aldrich, Munich, Germany) at 37°C for 
30min. The suspension was passed through a 100 µm strainer and hepatocytes were 
separated from NPC by centrifuging at 50g for 3min. NPC were washed with DMEM, 
treated with RBC lysis buffer (5min, RT) and washed again 3x at 200g for 10min to 
remove debris. Both hepatocytes and NPC were used for further procedures. 
 
Hepatic stellate cells isolation and proliferation activity assay 
Primary mouse hepatic stellate cells (HSC) were isolated as described previously (8). 
Briefly, WT and DKO mice fed a HFD for 15 weeks were anesthetized and perfusion 
of the liver through the portal vein was performed by using consecutively EGTA, 
Pronase E (0.5mg/ml, Sigma Aldrich) and Collagenase P (0.4mg/ml, Roche 
Diagnostics, Germany) containing buffers. The separated livers were further digested 
by a Pronase E (1mg/ml), collagenase P (0.4mg/ml) and DnaseI (2mg/ml, Roche 
Diagnostics, Germany) containing solution and filtered through a 70µm cell strainer. 
After washing with Gey’s balanced salt solution including DnaseI, HSC were purified 
from other hepatic cells and debris by centrifugation on a 8% Nycodenz gradient 
(Progen Biotechnik, Germany) at 1500g, for 15min, at 4°C without break. After 
washing, the separated HSC were stained with an anti-mouse CD45-PE antibody 
(eBioscience), fixed and permeabilized and further stained against proliferating cell 
nuclear antigen (PCNA)-FITC (Milipore) and phospho-S6 Ribosomal protein 
(Ser235/236)-Alexa Fluor 647 (Cell signaling). The CD45 negative and PCNA 
positive or pS6 positve cells were detected by flow cytometry on a FACS Canto II 
(BD, Heidelberg, Germany).  
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Adipose-tissue (AT) stromal vascular fraction (SVF) isolation 
Stromal vascular fraction (SVF) isolation was performed as previously described (4). 
Briefly, subcutaneous or gonadal AT from euthanized mice were isolated, minced and 
incubated at 37°C in DMEM containing collagenase type I (2 mg/ml per gram of 
tissue; Invitrogen, Darmstadt, Germany). The suspension was resuspended in DMEM-
0.5% BSA (Sigma Aldrich, Munich, Germany), centrifuged so as to separate 
adipocytes from the SVF, incubated then for 5 min with RBC lysis buffer 
(eBioscience, Frankfurt, Germany), and washed again before further analysis. 
 
Flow cytometry analysis 
For flow cytometry analysis, cells were resuspended in FACS buffer (HBSS Solution 
with 0.1% BSA and 0.1% NaN3) and filtered through a 40 µm cell strainer. Fc-
blocking (CD16/32 antibody, BD, Heidelberg, Germany) was applied and cells were 
stained with antibodies against CD4, CD8, CD3, CD25, FoxP3, CD11b, CD11c, 
F4/80, and CD206 purchased from Miltenyi Biotec (Bergisch Gladbach, Germany), e-
Biosciences (San Diego, CA, USA) BioLegend (Fell, Germany) or Acris Antibodies 
(Herford, Germany). Overnight fixation of cells with a fixation / permeabilization 
buffer (eBioscience, Frankfurt, Germany) was used when staining for CD206 or 
Foxp3 was performed. Flow cytometry was performed on a FACS Canto II (BD, 
Heidelberg, Germany) and data were analyzed by using FACSDiva Version 6.1.3 
software. 
 
Treg isolation from spleen 
Splenic cells were isolated from 8 week old mice and stained with anti-CD3e-PE, 
anti-CD4-FITC and anti-CD25-APC (Miltenyi Biotec). After pooling, the 
CD4+CD25+-Treg cells were sorted using a FACSAria II cell sorter (BD Biosciences). 
The sorted cells were collected into PBS with 0.5% BSA, washed twice with PBS and 
then injected into Dko mice (0.75x106 cells/mouse/week) as described under “Animal 
Studies and diets”. The purity of Treg cells was routinely >90%. 
 
Peritoneal macrophage polarization analysis 
Macrophage polarization was studied in peritoneal macrophages. Briefly, peritonitis 
was induced in 8 week old male wild type or Dko mice by intraperitoneal injection of 
1ml 3% thioglycollate (9, 10). After 3 days, macrophages were isolated by peritoneal 
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lavage with 15 ml 3% FBS PBS per mouse. Isolated cells were analyzed by FACS 
analysis for F4/80, CD11b and CD206 and by real-time PCR.   
 
Co-culture experiments 
For hepatocyte-liver NPC co-culture, cells were isolated as described above under 
“Hepatocyte and non-parenchymal cell (NPC) isolation”. Hepatocytes were plated 
overnight into 12-well collagen coated culture plates (3x105 cells / well), while NPC 
were incubated in suspension culture dishes in complete-DMEM containing 300 
ng/ml LPS. On day 2, both cell populations were washed with DMEM and NPC 
(106cells / well) were added into plates containing hepatocytes. The cells were co-
cultured for 24h in palmitate (500 μmol/l)-containing medium in the absence or 
presence of a combination of anti-B7.1 and anti-B7.2 or respective isotype controls 
(Bioceros, Utrecht, Netherlands) and supernatants were collected for further analysis. 
Palmitate preparation was done as described previously (11). 
 
Real-Time PCR analysis 
Total RNA was extracted with Trizol (Invitrogen, Darmstadt, Germany) and cDNA 
was synthesized with the iScript cDNA Synthesis Kit (Bio-Rad, Munich, Germany). 
PCRs were performed with a Bio-Rad cycler system (BioRad, Munich, Germany) 
using the SsoFast EvaGreen Supermix (BioRad) and gene-specific primers. The 
relative amount of the different mRNAs were quantified with the ΔΔCt method while 
the expression of 18S or actin mRNA was used for normalization among samples (12). 
The fold-change ratio was calculated. 
 
Immunohistochemistry and immunofluorescence 
For conventional light microscopy, livers were fixed in 4% paraformaldehyde solution 
overnight at 4oC. Tissues were embedded in paraffin, cut into 5 µm thick sections and 
subjected to hematoxylin / eosin and Picric acid Sirius red (Picrosirius) staining. The 
level of NAFLD/NASH was read blinded to experimental design and the degree of 
steatosis, lobular inflammation, ballooning was evaluated according to previously 
published criteria following the NASH-CRN Committee scoring system (13). 
Steatosis and inflammation were scored using a 0 to 3 scale, while ballooning by 
using a 0 to 2 scale. The NAFLD activity score (NAS) was defined as the sum of 
steatosis, lobular inflammation and ballooning, thus ranging from 0 to 8. 
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For histochemical staining with Oil Red O (ORO), 10 µm cryosections were prepared, 
slides were fixed in ice-cold 10% formalin solution for 10 minutes, rinsed in dH2O 
and stained for 15 minutes in ORO in 60% isopropanol solution (ORO:H2O, 3:2). 
Slides were then rinsed in 60% isopropanol and nuclei were counter-stained with 
Mayer’s haematoxylin. Slides were rinsed in H2O and mounted with 95% glycerol. 
  
A microscope coupled to a computerized system (Zeiss, Oberkochen, Germany) and 
equipped with the AxioVision Rel. 4.8 software (Carl-Zeiss MicroImaging GmbH, 
Jena, Germany) was used for the aforementioned experimental procedures. The Oil-
Red O or Picrosirius red positive areas were evaluated by using the ImageJ software 
(14).  
 
Statistical analysis 
Data are expressed as means ± SEM and a Student’s T-Test or a Mann–Whitney U 
test were used. The GTT and ITT results were analyzed by a 2-way ANOVA. 
Significance was set at P < 0.05. 
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Legends to supplementary figures 
 
Suppl. Figure 1 
Regulation of B7.1-B7.2 expression in obesity 
A) B7.1 and B7.2 gene expression was analyzed in liver and hepatic non-parenchymal 
cells (NPC) of WT male mice fed a ND or HFD for 15 weeks. The mRNA expression 
was normalized against 18S and the gene expression in liver or NPC from ND-fed 
mice was set as 1 (n= 5). Data are mean ± SEM, *p<0.05. B) B7.1 and B7.2 gene 
expression analysis was performed by qPCR in gonadal AT and stromal vascular 
fraction (SVF) from gonadal AT of WT male mice fed a normal (ND) or high fat 
(HFD) diet for 18 weeks. The mRNA expression was normalized to 18S and the 
B7.1/B7.2 expression under ND conditions served as control and was set as 1 (n= 5). 
Data are mean ± SEM, *p<0.05.  
 
Suppl. Figure 2 
Metabolic cage analysis in WT and Dko mice 
WT or Dko mice fed a ND or HFD for 8 weeks were housed in metabolic cages 
maintaining a 12h:12h light-dark cycle with free access to water and food. After 
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acclimatization (24 hours), volume of oxygen consumption (VO2) and carbon dioxide 
production (VCO2), respiratory exchange ratio (RER), energy expenditure (EE), 
locomotion and food and water intakes were monitored. Black bars mean dark cycles 
whereas white bars represent light cycles. n= 3/group for ND and n= 5/group for HFD. 
Data are mean ± SEM, *p<0.05 for comparison between WT and Dko mice fed the 
same diet. 
 
Suppl. Figure 3 
A) Metabolic parameters of WT and Dko mice fed a HFD for 18weeks. WT and 
Dko male mice were fed a HFD for a total of 18 weeks. The levels of leptin were 
measured by ELISA in sera (after sacrificing mice), while blood cholesterol and 
triglycerides were quantified by tail-vein blood sampling, 1-2 weeks before 
sacrificing the mice as described under Materials and Methods (n=at least 12). Data 
are mean ± SEM, *p<0.05. 
B) Hypothalamic inflammation in WT and Dko mice fed a HFD.  
Hypothalami from WT and Dko fed a HFD for 8 weeks were isolated and the mRNA 
expression of cellular and inflammatory markers were analyzed by qPCR. The mRNA 
expression was normalized against 18S and the gene expression of wild type mice 
was set as 1 (n=4). Data are mean ± SEM. 
 
Suppl. Figure 4 
Insulin signaling in liver and white AT of WT and Dko mice 
WT and Dko male mice were fed a HFD for 17 weeks. Mice were fasted overnight, 
insulin (2U/Kg) was injected intraperitoneally and tissues were collected after 7 min 
for immunoblotting. (A, C) Representative western blot analysis of insulin-induced 
AKT phosphorylation as well as total AKT from liver (A) and gonadal AT (C) is 
shown. (B, D) Densitometric analysis of the phosphorylated AKT/total AKT ratio in 
liver (B) and gonadal AT (D) is shown. Data are mean ± SEM, *p<0.05 for 
comparison between WT and Dko mice (n=4). 
 
Suppl. Figure 5 
A. B7.1-B7.2 Dko mice have reduced numbers of Treg cells 
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Total leukocytes were isolated from lymph node, spleen and blood of male WT and 
B7-double deficient (Dko) mice and analyzed by flow cytometry. 
CD4+CD25+Foxp3+ Treg cells are depicted as percentage of total leukocytes from 
lymph node, spleen and blood (n=4). Data are mean ± SEM, *p<0.05. 
B,C. Increased hepatic stellate cell activity in Dko mice 
Hepatic stellate cells (HSC) were isolated from livers of WT and Dko mice fed a HFD 
for 15 weeks. The freshly isolated HSC were analyzed by flow cytometry and CD45- 
cells were analysed for PCNA (B) or pS6 (C). Percentages of PCNA+ or pS6+ among 
the isolated stellate cell population as well as the mean fluorescense intensities (MFI) 
of PCNA or pS6 are shown. Data are mean ± SEM, *p<0.05 (n=5/group). PCNA: 
proliferating cell nuclear antigen, pS6: phospho-S6 ribosomal protein. 
 
Suppl. Figure 6 
Macrophage polarization in WT vs Dko mice 
Thioglycollate-elicited peritoneal macrophages were isolated from 8 week old male 
WT or Dko mice. A,B) Cells isolated by peritoneal lavage were stained for CD11b, 
F4/80 and CD206. CD206 was analyzed in CD11b+F4/80+ cells. A) Percentage of 
CD206+ cells and mean fluorescence values from WT and Dko mice. B) The gene 
expression of iNOS and IL-6 (M1-macrophages markers) in isolated cells from 
peritoneal lavage from WT and Dko mice was analysed by qPCR. The mRNA 
expression was normalized against 18S and the relative gene expression (gene 
expression / 18S expression ratio) is depicted (n= at least 6). Data are mean ± SEM, 
*p<0.05. 
 
Suppl. Figure 7 
Adoptive transfer of Treg cells does not reverse hepatic steatosis or metabolic 
dysregulation due to B7-deficiency 
Dko male mice were fed a HFD for 12 weeks, receiving 6 intraperitoneal injections of 
0.75x106 FACS-sorted CD4+CD25+ Treg cells (once per week starting from week 5 
until week 10) or control injections with PBS. A) Body weight of PBS- or Treg- 
injected Dko mice (Dko-CTRL and Dko-Treg-INJ mice, respectively) in grams is 
depicted. B) Glucose tolerance test after 11 weeks of feeding as described under 
Materials and Methods. C) Representative H&E staining in liver paraffin sections 
from PBS- or Treg-injected Dko mice is shown (x100 magnification). D) The mRNA 
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levels of lipid accumulation related genes (SREBP1C, Sterol Regulatory Element-
Binding Protein; CHREBP, Carbohydrate-responsive element-binding protein; TGF-
b, Transforming growth factor-beta) and inflammatory genes (TNF, IL-1b) were 
analyzed by qPCR. 18S expression was used for normalization of mRNA expression 
and the gene expression of PBS-injected mice (Dko CTRL) was set as 1. Data are 
mean ± SEM; n= 5. 
 
Suppl. Figure 8 
Antibody blockade of either B7.1 or B7.2 does not affect obesity-related 
metabolic dysregulation 
WT male mice were fed a HFD for a total of 16 weeks, receiving either anti-B7.1 or 
anti-B7.2 antibodies or respective isotype controls starting at week 4 of feeding 
(200μg of each antibody or isotype control were injected intraperitoneally per mouse, 
twice per week). (A) Body weight of HFD-fed anti-B7.1 or isotype control-injected 
mice in grams is depicted (n=at least 8) B) glucose and insulin tolerance tests of HFD-
fed anti-B7.1 or isotype control-injected mice were performed in weeks 15 and 16 of 
feeding, respectively, as described under Materials and Methods (n=at least 8). C) 
Body weight of HFD-fed anti-B7.2 or isotype control-injected mice in grams is 
depicted (n=at least 6). D) Glucose and insulin tolerance tests of HFD-fed anti-B7.2 
or isotype control-injected mice were performed in weeks 15 and 16 of feeding, 
respectively, as described under Materials and Methods (n=at least 6). Data are mean 
± SEM. 
 
Suppl. Figure 9 
Antibody-mediated B7 blockade improved hepatic insulin signaling.  
WT male mice were fed a HFD for a total of 11 weeks and received a combination of 
anti-B7.1 and anti-B7.2 antibodies (anti-B7.1/B7.2 WT mice) or isotype controls 
(CTRL WT mice) starting at week 4 of feeding (200μg of each antibody or isotype 
control were injected intraperitoneally per mouse, twice per week). 
Mice were fasted overnight, insulin (2U/Kg) was injected intraperitoneally and tissues 
were collected after 7 min for immunoblotting. (A) Representative western blot 
analysis of insulin-induced AKT phosphorylation as well as total AKT from liver is 
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shown. (B) Densitometric analysis of the phosphorylated AKT/total AKT ratio is 
shown. Data are mean ± SEM (n=4). 
 
Suppl. Figure 10. Metabolic cage analysis in isotype- and anti-B7.1/B7.2 treated 
mice 
WT male mice were fed a HFD for 8 weeks and also received a combination of anti-
B7.1 and anti-B7.2 antibodies (anti-B7.1/B7.2 WT mice) or isotype controls (CTRL 
WT mice) starting at week 4 of feeding (200μg of each antibody or isotype control 
were injected intraperitoneally per mouse, twice per week). Mice were then 
transferred to metabolic cages. After acclimatization (24h), respiratory exchange ratio 
(RER) (A), energy expenditure (EE) (B), food intake (C) and locomotion (D) were 
assessed in a metabolic monitoring system maintaining a 12h:12h light-dark cycle 
with free access to water and food for 3 days. Data are mean ± SEM; n= 3.  
 
Suppl. Figure 11 
Splenic Treg population does not change in HFD-fed mice upon anti-B7.1 and 
anti-B7.2 treatment 
WT male mice were fed a HFD for a total of 16 weeks and also received a 
combination of anti-B7.1 and anti-B7.2 antibodies (anti-B7.1/B7.2 WT mice) or 
isotype controls (CTRL WT mice) starting at week 4 of feeding (200μg of each 
antibody or isotype control were injected intraperitoneally per mouse, twice per week). 
Total leukocytes from spleen were isolated and CD4+CD25+Foxp3+ Treg cells were 
detected by FACS. Tregs are expressed as percentage of the total leukocytes isolated 
from spleen (n=8). Data are mean ± SEM. 
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Suppl. Table 1 
Metabolic cage analysis in WT and Dko mice under normal or high-fat diet 
 
 
 
 
 
 
 
 
 
 
 
Values represent Mean ± SEM. * p-value < 0.05 
 
 
 
 
 
 
 
 
 
 
 ND HFD 
 WT DKO WT DKO 
VO2 light (mL/h) 100.8 ± 3.8 104.2 ± 1.1 116.6 ± 2.8 127.3 ± 6.3 
VO2 dark (mL/h) 120.8 ± 1.2 121.9 ± 1.7 134.5 ± 7.0 141.6 ± 8.7 
VCO2 light (mL/h) 91.1 ± 5.6 97.8 ± 4.2 85.2 ± 1.9 94.9 ± 5.0 
VCO2 dark (mL/h) 116.1 ± 0.6 120.7 ± 1.3 99.8 ± 4.6 107.8 ± 7.3 
Food intake (g/h) 0.112 ± 0.007 0.121 ± 0.007 0.023 ± 0.006 0.039 ± 0.009 * 
Water intake (mL/h) 0.100 ± 0.006 0.142 ± 0.015 0.075 ± 0.010 0.067 ± 0.009 
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